Seres Therapeutics, Inc. (MCRB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
MCRB currently has 8.87M outstanding shares. with significant dilution risk as 76.5M authorized shares could dilute existing holders by 862.3%. The company has diluted shareholders by 16.58% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 12, 2026 |
10-K filing | 8.9M shares outstanding |
8.9M | 76M |
| Nov 05, 2025 |
10-Q filing | 8.8M shares outstanding |
8.8M | 77M |
| Aug 06, 2025 |
10-Q filing | 8.7M shares outstanding |
8.7M | 77M |
| May 07, 2025 |
10-Q filing | 8.7M shares outstanding |
8.7M | 77M |
| Mar 13, 2025 |
10-K filing | 174.4M shares outstanding |
170M | 0 |
| Nov 13, 2024 |
10-Q filing | 170.7M shares outstanding |
170M | 0 |
| Oct 01, 2024 |
S-3 filing: Seres Therapeutics, Inc. is offering 14,285,715 shares of common stock for resale by the selling stockholder; the company will not receive any proceeds from the sale. |
150M | 0 |
| Aug 13, 2024 |
10-Q filing | 151.5M shares outstanding |
150M | 0 |
| May 08, 2024 |
10-Q filing | 146.1M shares outstanding |
150M | 0 |
| Mar 05, 2024 |
10-K filing | 151.0M shares outstanding |
150M | 0 |
| Nov 02, 2023 |
10-Q filing | 128.3M shares outstanding |
130M | 0 |
| Aug 08, 2023 |
S-3 filing: Seres Therapeutics intends to sell shares of its common stock from time to time through TD Cowen, acting as its agent, via an at-the-market offering for an aggregate offering price of up to $132,983,352.19. |
130M | 0 |
| Aug 08, 2023 |
10-Q filing | 127.7M shares outstanding |
130M | 0 |
| May 09, 2023 |
10-Q filing | 125.9M shares outstanding |
130M | 0 |
| Mar 07, 2023 |
10-K filing | 126.1M shares outstanding |
130M | 0 |
| Nov 02, 2022 |
10-Q filing | 122.5M shares outstanding |
120M | 0 |
| Aug 03, 2022 |
10-Q filing | 124.1M shares outstanding |
120M | 0 |
| May 04, 2022 |
10-Q filing | 92.2M shares outstanding |
92M | 0 |
| May 04, 2022 |
POS AM filing: This is a POS AM filing related to exhibits including the Form of Underwriting Agreement. |
92M | 0 |
| Mar 01, 2022 |
10-K filing | 92.0M shares outstanding |
92M | 0 |
| Mar 01, 2022 |
POS AM filing: Seres Therapeutics, Inc. is offering common stock and preferred stock and debt securities with an aggregate value of up to $250,000,000 from time to time in one or more offerings. |
92M | 0 |
| Nov 10, 2021 |
10-Q filing | 91.8M shares outstanding |
92M | 0 |
| Aug 03, 2021 |
10-Q filing | 91.7M shares outstanding |
92M | 0 |
| May 04, 2021 |
10-Q filing | 91.6M shares outstanding |
92M | 0 |
| Mar 02, 2021 |
10-K filing | 91.5M shares outstanding |
92M | 0 |
| Nov 09, 2020 |
10-Q filing | 91.2M shares outstanding |
91M | 0 |
| Jul 28, 2020 |
10-Q filing | 76.3M shares outstanding |
76M | 0 |
| May 07, 2020 |
10-Q filing | 72.6M shares outstanding |
73M | 0 |
| Mar 09, 2020 |
S-3 filing: SERES THERAPEUTICS, INC. is filing an S-3 to offer and sell up to $125,000,000 in the aggregate of Common Stock, Preferred Stock, and Debt Securities. |
71M | 0 |
| Mar 02, 2020 |
10-K filing | 71.1M shares outstanding |
71M | 0 |